← Search & browse all drugs

hyaluronic acid, combinations

S01KA51

Forms & Strengths

ophthalmic solution 0.1% hyaluronic acid + 0.1% dexamethasone
ophthalmic suspension 0.2% hyaluronic acid + 0.1% dexamethasone

Adult Dosing

post‑operative: 1 drop into the affected eye 4 times daily for 7‑14 days
dry‑eye adjunct: 1‑2 drops 3‑4 times daily as needed

Pediatric Dosing

children ≥2 yr: same regimen as adults, monitor intra‑ocular pressure closely
children <2 yr: use only if benefit outweighs risk, under specialist supervision

Indications

post‑cataract and intra‑ocular surgery inflammation and pain
post‑laser keratorefractive procedures
ocular surface lubrication in dry‑eye disease
uveitis adjunct therapy (short‑term)

Mechanism of Action

hyaluronic acid provides viscoelastic lubrication, stabilises tear film and promotes epithelial healing
dexamethasone binds glucocorticoid receptors, suppresses inflammatory cytokine production and leukocyte migration

Contraindications

hypersensitivity to hyaluronic acid, dexamethasone or excipients
active viral ocular infection (e.g., herpes simplex keratitis)
untreated or uncontrolled glaucoma
ocular tuberculosis or fungal infection

Adverse Reactions

temporary blurred vision or visual disturbance
ocular irritation, burning or stinging on instillation
increased intra‑ocular pressure (risk of steroid‑induced glaucoma)
cataract progression with prolonged use
secondary ocular infection

Drug Interactions

concomitant topical or systemic corticosteroids may potentiate IOP rise
non‑steroidal anti‑inflammatory eye drops may increase risk of corneal epithelial toxicity when used together
systemic CYP3A4 inducers can reduce dexamethasone efficacy

Curated Content: Needs Vetting Before Put to Clinical Use